Radiation Oncology Journal最新文献

{"title":"Late toxicities in locally advanced head and neck squamous cell carcinoma treated with intensity modulated radiation therapy.","authors":"Sandeep Muzumder,&nbsp;Nirmala Srikantia,&nbsp;Avinash H Udayashankar,&nbsp;Prashanth Bhat Kainthaje,&nbsp;M G John Sebastian,&nbsp;John Michael Raj","doi":"10.3857/roj.2020.00913","DOIUrl":"https://doi.org/10.3857/roj.2020.00913","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to report late toxicities in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) treated with intensity-modulated radiation therapy (IMRT).</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on 103 patients of LAHNSCC treated with IMRT. We analyzed the cumulative incidence of late xerostomia, dysphagia, and aspiration at an interval of 6-month, 1-year, 2-year, and 3-year from the start of IMRT.</p><p><strong>Results: </strong>At a median follow up of 4.2 years (interquartile range, 3.5 to 6 years), the cumulative incidence of grade ≥2 late xerostomia was 5.5%, dysphagia was 6.9%, and aspiration was 11.1%. Logistic regression showed that Dmean of ≥26 Gy to parotids had higher risk of xerostomia (hazard ratio [HR] = 5.19; 95% confidence interval [CI], 1.90-14.22; p = 0.001). Late dysphagia was associated with Dmean of ≥45 Gy to pharyngeal constrictors (PC) (HR = 7; 95% CI, 1.84-26.61; p =0.004), ≥55 Gy to larynx (HR = 3.25; 95% CI, 1.15-9.11; p = 0.025), and adjuvant RT (HR = 5.26; 95% CI, 1.85-14.87; p = 0.002). Aspiration was associated with Dmean of ≥45 Gy to larynx (HR = 6.5; 95% CI, 1.93-21.88; p = 0.003), Dmean of ≥55 Gy to PC (HR = 3.54; 95% CI, 1.25-9.98; p = 0.017), and patients having late dysphagia (HR = 4.37; 95% CI, 1.55-12.31; p = 0.005).</p><p><strong>Conclusion: </strong>IMRT is a feasible radiation delivery technique in LAHNSCC with a decreased late toxicity profile.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"184-192"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/b8/roj-2020-00913.PMC8497871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single photon emission computed tomography-computed tomography visualization of sentinel lymph nodes for lymph flow guided nodal irradiation in oral tongue cancer.","authors":"Sergey Nikolaevich Novikov,&nbsp;Pavel Ivanovich Krzhivitskii,&nbsp;Zamira Achmedovna Radgabova,&nbsp;Maxim Andreevitch Kotov,&nbsp;Mikhail Markovich Girshovich,&nbsp;Anna Sergeevna Artemyeva,&nbsp;Yulia Sergeevna Melnik,&nbsp;Sergey Vasilevich Kanaev","doi":"10.3857/roj.2021.00395","DOIUrl":"https://doi.org/10.3857/roj.2021.00395","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate correlation of single photon emission computed tomography-computed tomography (SPECT-CT) data on lymph flow (LF) from oral tongue cancer (OC) and the topography of lymph nodes (LN) metastases; to determine the clinical value of lymph flow guided radiotherapy (LFGRT).</p><p><strong>Materials and methods: </strong>SPECT-CT visualization of LF from the OC lesions was performed after peritumoral injection of 99mTc-phytate in 26 primary patients with clinical stage cT1-2N0M0 disease. We determined the individual drainage (unilateral/bilateral) from the tumor, and localization of sentinel LNs according to the neck levels. Metastases in LNs were verified with histology and a 2-year follow-up.</p><p><strong>Results: </strong>SPECT-CT detected bilateral LF in 10 (38.5%) of 26 patients; in 16 (61.5%) cases the drainage was unilateral. Histology revealed LNs metastases in three cases; regional recurrences were diagnosed in other four patients. In all seven observations metastases were located at the same site and level as the sentinel LNs. In eight (30.8%) of 26 patients sentinel LNs were visualized unilaterally at levels Ib-IIa; in five cases, unilaterally at levels I-IIa-III. In these patients, LFGRT demonstrated 59%-70% reduction of irradiated volume, and 26%-42% and 51%-70% decrease of the mean dose to the spinal cord and the contralateral parotid gland. In patients with a bilateral drainage the reduction of doses absorbed by the spinal cord and contralateral parotid gland was 19% and 6%, respectively.</p><p><strong>Conclusion: </strong>Localization of sentinel LNs determined by SPECT-CT corresponds to the localization of metastatic LNs in terms of side and levels.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"193-201"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/dc/roj-2021-00395.PMC8497868.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience.","authors":"Yoon Young Jo,&nbsp;Su Ssan Kim,&nbsp;Si Yeol Song,&nbsp;Eun Kyung Choi","doi":"10.3857/roj.2021.00696","DOIUrl":"https://doi.org/10.3857/roj.2021.00696","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the effectiveness of salvage radiation therapy (RT) in patients with locoregional recurrence (LRR) following initial curative resection of non-small cell lung cancer (NSCLC) and identify the prognostic factors affecting survival.</p><p><strong>Materials and methods: </strong>Between January 2009 and January 2019, 54 patients with LRR after NSCLC surgery were treated with salvage RT (83.3%) or concurrent chemoradiation therapy (16.7%). Twenty-three (42.6%), 21 (38.9%), and 10 (18.5%) patients had local, regional, and both recurrences, respectively. The median RT dose was 66 Gy (range, 37.5 to 70 Gy). The radiation target volume included recurrent lesions with or without regional lymphatics depending on the location and recurrence type.</p><p><strong>Results: </strong>The median follow-up time from the start of RT was 28.3 months (range, 2.4 to 112.4 months) and disease-free interval (DFI) from surgery to recurrence was 21.0 months (range, 0.5 to 92.3 months). Tumor response after RT was complete response, partial response, stable disease, and progressive disease in 17, 29, 5, and 3 patients, respectively. The rates of freedom from local progression at 1 and 2 years were 77.2% and 66.0%, respectively. The median survival duration after RT was 24.8 months, and the 2-year overall survival (OS) rate was 51.1%. On univariate analysis, initial stage, recurrence site, DFI, and tumor response after RT were significant prognostic factors for OS. DFI ≥12 months and tumor response after RT were statistically significant factors on multivariate Cox analysis for OS.</p><p><strong>Conclusion: </strong>Our results demonstrated the effectiveness of salvage RT for LRR of NSCLC following curative surgery.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"210-218"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/a8/roj-2021-00696.PMC8497866.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose escalated simultaneous integrated boost of gross nodal disease in gynecologic cancers: a multi-institutional retrospective analysis and review of the literature.","authors":"Garrett Lee Jensen,&nbsp;Megan Ann Mezera,&nbsp;Salman Hasan,&nbsp;Kendall Pye Hammonds,&nbsp;Gregory Peter Swanson,&nbsp;Moataz Nier El-Ghamry","doi":"10.3857/roj.2020.00948","DOIUrl":"https://doi.org/10.3857/roj.2020.00948","url":null,"abstract":"<p><strong>Purpose: </strong>Typical doses of 45-50.4 Gy used to treat regional nodes have demonstrated inadequate control of gross nodal disease (GND) in gynecologic cancer, and accelerated repopulation may limit the efficacy of a sequential boost. We reviewed outcomes of patients treated with a simultaneous integrated boost (SIB) at 2.25 Gy per fraction to positron emission tomography (PET) avid GND to evaluate toxicity and tumor control using this dose-escalated regimen.</p><p><strong>Materials and methods: </strong>A total of 83 patients with gynecologic cancer and PET avid inguinal, pelvic, or para-aortic lymphadenopathy were treated using intensity-modulated radiation therapy (IMRT) with SIB. Primary cancers were mostly cervical (51%) and endometrial (34%), and included patients who received concurrent chemotherapy (59%) and/or brachytherapy boost (78%).</p><p><strong>Results: </strong>Median follow-up from radiation completion was 12.6 months (range, 2.7 to 92.9 months). Median dose to elective lymphatics was 50.4 Gy (range, 45 to 50.4 Gy) at 1.8 Gy/fraction. Median SIB dose and volume were 63 Gy (range, 56.3 to 63 Gy) and 72.8 mL (range, 6.8 to 1,134 mL) at 2-2.25 Gy/fraction. Nodal control was 97.6% in the SIB area while 90.4% in the low dose area (p = 0.013). SIB radiotherapy (RT) field failure-free, non-SIB RT field failure-free, and out of RT field failure-free survival at 4 years were 98%, 86%, and 51%, respectively. Acute and late grade ≥3 genitourinary toxicity rates were 0%. Acute and late grade ≥3 gastrointestinal toxicity rates were 7.2% and 12.0%, respectively.</p><p><strong>Conclusion: </strong>Dose escalated SIB to PET avid adenopathy results in excellent local control with acceptable toxicity.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"219-230"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1b/bd/roj-2020-00948.PMC8497864.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early toxicities of ultrahypofractionated stereotactic body radiotherapy for intermediate risk localized prostate cancer using cone-beam computed tomography and real-time three-dimensional transperineal ultrasound monitoring.","authors":"Eric Ka-Chai Lee,&nbsp;Ronnie Wing-Kin Leung,&nbsp;Hollis Siu-Leung Luk,&nbsp;Barry Bar-Wai Wo","doi":"10.3857/roj.2020.00969","DOIUrl":"https://doi.org/10.3857/roj.2020.00969","url":null,"abstract":"<p><strong>Purpose: </strong>Image-guided radiotherapy (IGRT) is central to the safe and effective delivery of ultrahypofractionated (UF) stereotactic body radiotherapy (SBRT) for localized prostate cancer. However, the optimal IGRT modality remains uncertain. We aim to study the safety of performing UF-SBRT using cone-beam computed tomography (CBCT) and real-time transperineal ultrasound (TPUS) monitoring.</p><p><strong>Materials and methods: </strong>We retrospectively review the medical records of 26 patients who had received UF-SBRT for intermediate risk localized prostate cancer in our institution from October 2018 to December 2020. All patients were treated with SBRT without fiducial marker and received 35-40 Gy to the clinical target volume in 5 fractions over 2-5 weeks. CBCT was used to correct for interfraction displacement while intrafraction displacement of the prostate gland was monitored using Elekta Clarity Autoscan TPUS with 4 mm isotropic warning level. All patients also received neoadjuvant and concurrent androgen deprivation therapy for a total of 6 months. The primary endpoints were incidence of acute toxicities and patient reported urinary toxicities in terms of the International Prostate Symptom Score: before (IPSS1), at the completion of (IPSS2), and at 3-6 months (IPSS3) after SBRT.</p><p><strong>Results: </strong>All men were treated and followed up for at least 3 months after SBRT. Patients experienced transient worsening of their urinary symptoms at the end of SBRT but they usually recovered in 3-6 months afterwards. The median IPSS1, IPSS2, and IPSS3 were 12, 12.5, and 8, respectively. One patient developed grade 3 rectal bleeding which was related to underlying hemorrhoid. No other grade 3-4 acute toxicity was observed.</p><p><strong>Conclusion: </strong>It appears safe to deliver UF-SBRT without fiducial marker for prostate cancer patients using CBCT and non-invasive hybrid imaging modalities for positioning and tracking. Longer follow-up is necessary to monitor the treatment efficacy and long-term toxicities.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"239-245"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/e5/roj-2020-00969.PMC8497869.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39488921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer.","authors":"Ye Jin Yoo,&nbsp;Su Ssan Kim,&nbsp;Si Yeol Song,&nbsp;Jong Hoon Kim,&nbsp;Seung Do Ahn,&nbsp;Sang-Wook Lee,&nbsp;Sang Min Yoon,&nbsp;Young Seok Kim,&nbsp;Jin-Hong Park,&nbsp;Jinhong Jung,&nbsp;Eun Kyung Choi","doi":"10.3857/roj.2021.00416","DOIUrl":"https://doi.org/10.3857/roj.2021.00416","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT) at our institution.</p><p><strong>Materials and methods: </strong>From May 2007 to December 2018, HFRT was used to treat 68 lesions in 64 patients who were unsuitable for SBRT because of central tumor location, large tumor size, or contiguity with the chest wall. The HFRT schedule included a dose of 50-70 Gy delivered in 10 fractions over 2 weeks. The primary outcome was freedom from local progression (FFLP), and the secondary endpoints included overall survival (OS), disease-free survival, and toxicities.</p><p><strong>Results: </strong>The median follow-up period was 25.5 months (range, 5.3 to 119.9 months). The FFLP rates were 79.8% and 67.8% at 1 and 2 years, respectively. The OS rates were 82.8% and 64.1% at 1 and 2 years, respectively. A larger planning target volume was associated with lower FFLP (p = 0.023). Dose escalation was not associated with FFLP (p = 0.964). Four patients (6.3%) experienced grade 3-5 pulmonary toxicities. Tumor location, central or peripheral, was not associated with either grade 3 or higher toxicity.</p><p><strong>Conclusion: </strong>HFRT with 50-70 Gy in 10 fractions demonstrated acceptable toxicity; however, the local control rate can be improved compared with the results of SBRT. More studies are required in patients who are unfit for SBRT to investigate the optimal fractionation scheme.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"202-209"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/17/roj-2021-00416.PMC8497873.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39511387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytogenetic biological dosimetry assays: recent developments and updates.","authors":"Tamizh Selvan Gnanasekaran","doi":"10.3857/roj.2021.00339","DOIUrl":"https://doi.org/10.3857/roj.2021.00339","url":null,"abstract":"<p><p>Biological dosimetry is the measurement of radiation-induced changes in the human to measure short and long-term health risks. Biodosimetry offers an independent means of obtaining dose information and also provides diagnostic information on the potential for \"partial-body\" exposure information using biological indicators and otherwise based on computer modeling, dose reconstruction, and physical dosimetry. A variety of biodosimetry tools are available and some features make some more valuable than others. Among the available biodosimetry tool, cytogenetic biodosimetry methods occupy an exclusive and advantageous position. The cytogenetic analysis can complement physical dosimetry by confirming or ruling out an accidental radiological exposure or overexposures. We are discussing the recent developments and adaptability of currently available cytogenetic biological dosimetry assays.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"159-166"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/80/roj-2021-00339.PMC8497872.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39487091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.","authors":"Seok-Joo Chun,&nbsp;Jin Ho Kim,&nbsp;Ja Hyeon Ku,&nbsp;Cheol Kwak,&nbsp;Eun Sik Lee,&nbsp;Suzy Kim","doi":"10.3857/roj.2021.00486","DOIUrl":"https://doi.org/10.3857/roj.2021.00486","url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP).</p><p><strong>Materials and methods: </strong>Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS).</p><p><strong>Results: </strong>Of 583 patients met the inclusion criteria (77 EBRT and 506 RP). The estimated 10-year PCSS was 97.0% in the RP and 95.9% in the EBRT (p = 0.770). No significant difference was seen in the DMFS (p = 0.540), whereas there was a trend in favor of RP over EBRT in overall survival (OS) (p = 0.068). Propensity score matching analysis with confounding variables was done, with 183 patients (66 EBRT and 117 RP) were included. No significant difference in DMFS, PCSS or OS was found.</p><p><strong>Conclusion: </strong>Our data demonstrated similar oncologic PCSS, OS, and DMFS outcomes between EBRT and RP patients.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 3","pages":"231-238"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/eb/roj-2021-00486.PMC8497867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39488920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review.","authors":"Peiman Haddad,&nbsp;Reza Ghalehtaki,&nbsp;Arefeh Saeedian,&nbsp;Farshid Farhan,&nbsp;Mohammad Babaei,&nbsp;Mahdi Aghili","doi":"10.3857/roj.2021.00108","DOIUrl":"https://doi.org/10.3857/roj.2021.00108","url":null,"abstract":"<p><p>Rectal cancer is one of the most prevalent cancers in the world. In many countries, the current standard of care is long-course chemoradiation (CRT), followed by total mesorectal excision. Some efforts have been made by intensifying radiation or chemotherapy components of the neoadjuvant therapy to further decrease the local recurrence and augment surgery's feasibility and improve the oncological outcomes. This paper reviews recent intensified neoadjuvant interventions in locally advanced rectal cancer (LARC) in terms of efficacy and treatment-related toxicity. Many maneuvers have been made so far to improve the oncological outcomes of rectal cancer with intensified neoadjuvant long-course CRT. Some of these approaches seem compelling and deserve further study, while some have just increased the treatment-related toxicities without evident benefits. Those endeavors with greater pathological complete response than the standard of care may make us await the long-term results on survival rates and chronic treatment-related toxicity. After introduction of neoadjuvant CRT for LARC there have been many efforts to improve its outcomes. Here, this study gathered most of these efforts that intensified the neoadjuvant therapy with some being promising and some being futile.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 2","pages":"83-90"},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/62/roj-2021-00108.PMC8497854.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39497061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrathyroidal parathyroid carcinoma: a case report and literature review.","authors":"Kenza Benali,&nbsp;Jihan Aarab,&nbsp;Houda Benmessaoud,&nbsp;Abdelati Nourreddine,&nbsp;Sanaa El Majjaoui,&nbsp;Hanan El Kacemi,&nbsp;Tayeb Kebdani,&nbsp;Noureddine Benjaafar","doi":"10.3857/roj.2020.01060","DOIUrl":"https://doi.org/10.3857/roj.2020.01060","url":null,"abstract":"<p><p>Parathyroid carcinoma is an uncommon endocrine malignancy comprising 0.5%-2% of patients with primary hyperparathyroidism. The probability of an intrathyroidal location is low (0.2%) and make preoperative suspicion and diagnosis challenging. Less than 20 cases of intrathyroidal parathyroid carcinoma have been reported. We introduce a case of intrathyroidal parathyroid carcinoma mimicking a suspicious thyroid nodule, and review the literature, with a focus on the role of adjuvant radiotherapy.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"39 2","pages":"145-151"},"PeriodicalIF":2.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/9d/roj-2020-01060.PMC8497858.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38882001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}